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Cardiotoxicity and
myocardial hypoperfusion
associated with anti-vascular
endothelial growth factor
therapies: prospective
cardiac magnetic resonance
imaging in patients
with cancer
By interrupting tumour angiogenesis, vas-
cular endothelial growth factor signalling
pathway inhibitors (VSPIs) represent a major
advance in the treatment of a wide variety of
cancers.1 However, their oncological benefits
have been accompanied by considerable car-
diovascular toxicity, including hypertension,
left ventricular systolic dysfunction (LVSD)
and heart failure.2 These may be severe and
can limit the dose and duration of anti-cancer
treatment.
The timing, frequency, and pathophysio-
logical basis of VSPI-associated myocardial
toxicity is incompletely defined. In addition
to the detrimental effect of an abrupt rise
in left ventricular afterload as a result of
VSPI-associated hypertension, inhibition of
vascular endothelial growth factor may have
direct myocardial toxic effects. This may be
the consequence of inhibition of tyrosine
kinases required both for tumour growth and
normal cardiac function. Furthermore, VSPIs
are associated with peripheral microvascular
rarefaction3 and it remains unclear whether
myocardial micro-arterial constriction or
vessel loss is implicated in the pathogenesis of
VSPI-associated LVSD. The only prior study
to evaluate prospectively the effects of VSPIs
upon cardiac function used echocardiogra-
phy and demonstrated a 9.7% incidence of
cardiotoxicity, defined as ≥10% reduction
in left ventricular ejection fraction (LVEF) to
a value less than 50%.4 There are inherent
limitations of echocardiography for the repro-
ducible detection of changes in myocardial
function and it does not allow assessment of
myocardial perfusion, vascular permeability,
or myocardial tissue characterisation. We
therefore used multi-parametric cardiac
magnetic resonance imaging, including adeno-
sine stress-perfusion to measure myocardial
blood flow and vascular permeability in
patients before and during VSPI treatment.5
All patients over the age of 18 years at the
Beatson West of Scotland Cancer Centre
in Glasgow, Scotland, who were planned to
commence VSPI therapy were considered for
participation. Enrolment took place between
December 2018 and March 2019. Exclusion
criteria included an estimated glomerular
filtration rate < 30 mL/min/1.73 m2 of body
surface area, persistent or permanent atrial
fibrillation, second- or third-degree atrioven-
tricular block, and a history of allergy to
adenosine or gadolinium contrast.
Patients underwent stress-perfusion car-
diac magnetic resonance imaging (3.0T
Siemens MAGNETOM Prisma; Siemens
Healthcare, Erlangen, Germany) at base-
line and after 4 to 6 weeks of treatment.
Biventricular mass and function, myocardial
feature-tracking strain, and tissue character-
isation by T1 mapping and perfusion imaging
were assessed. Myocardial T1 mapping mea-
sures the myocardial longitudinal magnetic
relaxation time (also known as spin–lattice
relaxation time) of different molecules found
within the myocardium. Intravenous adeno-
sine infusion was used to induce hyperaemia
to simulate myocardial stress.
Ten patients were enrolled. All had incur-
able cancer. One withdrew because of severe
tumour-related symptoms. The average
age was 60.8 ± 7.5 years and most partic-
ipants were male (n = 7). Eight had renal
cell cancer and one patient had sarcoma.
VSPI therapies included pazopanib (n = 6),
sunitinib (n = 2) and tivozanib (n =1). Car-
diovascular comorbidities were common
at baseline, including hypertension (56%)
and hypercholesterolaemia (22%). The aver-
age body mass index was 29.3 ± 4.4 kg/m2.
Eight patients (89%) developed new or
worsening hypertension with VSPI ther-
apy. Both systolic and diastolic blood
pressure increased after 4 weeks of treat-
ment by 27.6 ± 22.0 mmHg (P = 0.006) and
18.8 ± 11.2 mmHg (P = 0.001), respectively.
After 4 weeks of VSPI treatment, LVEF fell
from 55.9 ± 3.1% to 51.0 ± 3.8% (P = 0.019)
and five patients had a reduction in LVEF of at
least 5% (Figure 1A). Myocardial T1 relaxation
times reduced from 1239 ms [interquartile
range (IQR) 1222–1247 ms] at baseline, to
1165 ms (IQR 1147–1222 ms) at follow-
up (P = 0.038). Extra-cellular volume also
declined from 26.9 ±1.2% to 24.4 ± 1.0%
(P = 0.047) at 4–6 weeks (Figure 1B and 1C).
After 4–6 weeks, resting myocardial blood
flow was 18% lower than baseline (P = 0.002)
(Figure 1D) but adenosine-induced stress
myocardial blood flow was unchanged by
VSPI treatment (P = 0.152). Additionally,
after 4–6 weeks, there was an increase in
contrast agent extraction fraction (a marker
of vascular permeability) at rest (P = 0.041),
with no change during adenosine-induced
stress (P = 0.772) (Figure 1E and 1F).
In this hypothesis-generating study, VSPI
therapy was associated with a reduction in
LVEF and it is possible that the incidence
of a more substantial drop in LVEF decline
may be greater than previously appreciated.
Although systemic hypertension may con-
tribute to these phenomena, alterations in
myocardial tissue characteristics, including
reduced T1 relaxation time, may reflect
direct myocardial toxic effects. The observed
rise in vascular permeability supports a role
for microvascular endothelial dysfunction in
the development of VSPI-associated LVSD.
Furthermore, reduced resting myocardial
blood flow is consistent with VSPI-induced
microvascular constriction and consequent
myocardial hypoperfusion. The normalisation
of myocardial blood flow with adenosine-
induced stress suggests that VSPI-induced
microvascular vasoconstriction may be
reversible and that vasodilator agents might
be a potential strategy to prevent or treat the
early cardiotoxic effects of VSPI. It remains to
be established whether such microvascular
changes remain reversible in patients exposed
to VSPI therapies and indeed, whether
any of the potential cardiotoxic effects
or injury sustained or progressed in the
longer term.
Further prospective evaluation of larger
groups of patients is necessary to provide
robust data relating to the incidence and
pathophysiology of VSPI-induced cardiotox-
icity. This is required urgently to allow
balanced decision-making before prescribing
these effective anti-cancer therapies whilst
minimising cardiovascular risk. Optimised
cardiovascular surveillance strategies and
mechanistically-targeted strategies to reduce
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Figure 1 Changes in (A) left ventricular ejection fraction, (B) T1 relaxation time, (C) extracellular volume, (D) myocardial blood flow at rest
and (E) stress, and (F) vascular permeability at rest with 4–6 weeks of vascular endothelial growth factor signalling pathway inhibitor therapy.
VSPI-induced cardiovascular toxicity are both
overdue.
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